Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/2b Study of KRT-232 Versus Ruxolitinib in Phlebotomy-Dependent Polycythemia Vera
2018-001672-38Phase 2Completed
- Sponsor
- Kartos Therapeutics
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of navtemadlin in polycythemia vera (PV) (2 arms), sponsored by Kartos Therapeutics. Primary endpoint: Part A primary objectives. Started Sep 2018; status: completed.
02
Drugs
navtemadlin
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2018-001672-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001672-38.